
1. transplantation. 2014 oct 27;98(8):835-43. doi: 10.1097/tp.0000000000000327.

adeno-associated viral vector 2.9 thymosin ß4 application attenuates rejection
after heart transplantation: results preclinical study pig.

postrach j(1), schmidt m, thormann m, thein e, burdorf l, reichart b, sotlar k,
walz c, faber c, bauer a, schmoeckel m, kupatt c, hinkel r.

author information: 
(1)1 herzchirurgischen klinik und poliklinik, klinikum großhadern, lmu, munich,
germany. 2 dzhk (german center cardiovascular research), partner site munich 
heart alliance, munich, germany. 3 institut für chirurgische forschung am
walter-brendel-zentrum für experimentelle medizin, lmu, munich, germany. 4
pathologisches institut, ludwig-maximilians-universität münchen. 5 klinik für
anästhesiologie, klinikum großhadern, lmu, munich, germany. 6 medizinische klinik
und poliklinik i, klinikum großhadern, lmu, munich, germany. 7 address
correspondence to: rabea hinkel, d.v.m., medizinische klinik und poliklinik i,
klinikum großhadern, lmu, marchioninistr. 15, 81377 münchen.

background: graft survival important factor morbidity and
mortality cardiac transplantation. improved immunosuppression significantly
reduced early graft rejection. however, acute rejection may predispose chronic
rejection. targeting phases recipient's immune-reactivity means of
long-acting recombinant adeno-associated viral vectors (aavs) encoding
anti-inflammatory cardioprotective factors appears promising
therapeutic approach. investigate thymosin ß4 (tß4) possessing
anti-inflammatory prosurvival abilities, means pretransplant gene
therapy.
methods: heterotopic, abdominal transplantation cardiac allografts into
landrace munich mini pigs (n=5 per group) performed. transplants were
transduced aav2.9 transplantation means situ perfusion of
the donor organ. vascuar endothelial growth factor aav2.9.tß4 aav2.9.lacz 
were added autologous blood used perfusing grafts period 
45 min. immunosuppression applied 10 days operation. transgene 
expression, capillary density, graft function, survival, rejection were
assessed.
results: aav2.9 transduction induced robust overexpression transgene. 
in addition, tß4 ameliorated inflammation, necrosis, vascular reaction (acute
rejection) parallel improved capillary density. addition, graft
survival significantly prolonged (10±3 days aav2.9.lacz vs. 31±4 days
aav2.9.tß4). mini pig model, regional myocardial function grafts
was improved tß4 transduction compared lacz (9.1%±0.9% subendocardial
segment shortening aav2.9.lacz vs. 15.8%±2.3% aav2.9.tß4).
conclusion: situ aav2.9-mediated gene transfer thymosin β4 attenuated graft
rejection heterotopic heart transplantation model. perioperative
cardioprotection means gene therapy might improve graft survival cardiac
allotransplantation.

doi: 10.1097/tp.0000000000000327 
pmid: 25321165  [indexed medline]

